Characteristics of patients in this study cohort, based on molecular subtypes
| . | GCB . | DZsigpos . | ABC . | UNC . | P value . | P value∗ . | P value† . |
|---|---|---|---|---|---|---|---|
| Number of patients | 367 | 65 | 468 | 150 | |||
| Age, y (n, %) | |||||||
| Median | 70 | 70 | 73 | 73 | |||
| <61 | 81 (22.1) | 13 (20) | 67 (14.3) | 22 (14.7) | .022 | 1 | .027 |
| ≥61 | 286 (77.9) | 52 (80) | 401 (85.7) | 128 (85.3) | |||
| Sex (n, %) | |||||||
| Male | 197 (53.7) | 43 (66.2) | 266 (56.8) | 85 (56.7) | .304 | .467 | 1 |
| Female | 170 (46.3) | 22 (33.8) | 202 (43.2) | 65 (43.3) | |||
| Performance status (n, %) | |||||||
| 0-1 | 307 (84.3) | 51 (79.7) | 369 (80) | 126 (85.1) | .205 | 1 | .729 |
| 2-4 | 57 (15.7) | 13 (20.3) | 92 (20) | 22 (14.9) | |||
| NA | 3 | 1 | 7 | 2 | |||
| Stage (n, %) | |||||||
| I/II | 199 (54.2) | 28 (43.1) | 184 (39.3) | 62 (41.3) | < .001 | .641 | < .001 |
| III/IV | 168 (45.8) | 37 (56.9) | 284 (60.7) | 88 (58.7) | |||
| LDH level (n, %) | |||||||
| Normal | 182 (49.6) | 17 (26.2) | 139 (29.7) | 61 (40.9) | < .001 | .003 | < .001 |
| >ULN | 185 (50.4) | 48 (73.8) | 329 (70.3) | 88 (59.1) | |||
| NA | 0 | 0 | 0 | 1 | |||
| Extranodal sites (n, %) | |||||||
| 0-1 | 305 (83.1) | 51 (78.5) | 355 (75.9) | 119 (79.3) | .085 | 1 | .077 |
| ≥2 | 62 (16.9) | 14 (21.5) | 113 (24.1) | 31 (20.7) | |||
| IPI risk group (n, %) | |||||||
| Low (0-1) | 140 (38.5) | 14 (21.9) | 98 (21.3) | 37 (25.5) | < .001 | .092 | < .001 |
| Low-intermediate (2) | 89 (24.5) | 17 (26.6) | 121 (26.2) | 37 (25.5) | |||
| High-intermediate (3) | 74 (20.3) | 20 (31.3) | 117 (25.4) | 42 (29) | |||
| High (4-5) | 61 (16.8) | 13 (20.3) | 125 (27.1) | 29 (20) | |||
| NA | 3 | 1 | 7 | 5 |
| . | GCB . | DZsigpos . | ABC . | UNC . | P value . | P value∗ . | P value† . |
|---|---|---|---|---|---|---|---|
| Number of patients | 367 | 65 | 468 | 150 | |||
| Age, y (n, %) | |||||||
| Median | 70 | 70 | 73 | 73 | |||
| <61 | 81 (22.1) | 13 (20) | 67 (14.3) | 22 (14.7) | .022 | 1 | .027 |
| ≥61 | 286 (77.9) | 52 (80) | 401 (85.7) | 128 (85.3) | |||
| Sex (n, %) | |||||||
| Male | 197 (53.7) | 43 (66.2) | 266 (56.8) | 85 (56.7) | .304 | .467 | 1 |
| Female | 170 (46.3) | 22 (33.8) | 202 (43.2) | 65 (43.3) | |||
| Performance status (n, %) | |||||||
| 0-1 | 307 (84.3) | 51 (79.7) | 369 (80) | 126 (85.1) | .205 | 1 | .729 |
| 2-4 | 57 (15.7) | 13 (20.3) | 92 (20) | 22 (14.9) | |||
| NA | 3 | 1 | 7 | 2 | |||
| Stage (n, %) | |||||||
| I/II | 199 (54.2) | 28 (43.1) | 184 (39.3) | 62 (41.3) | < .001 | .641 | < .001 |
| III/IV | 168 (45.8) | 37 (56.9) | 284 (60.7) | 88 (58.7) | |||
| LDH level (n, %) | |||||||
| Normal | 182 (49.6) | 17 (26.2) | 139 (29.7) | 61 (40.9) | < .001 | .003 | < .001 |
| >ULN | 185 (50.4) | 48 (73.8) | 329 (70.3) | 88 (59.1) | |||
| NA | 0 | 0 | 0 | 1 | |||
| Extranodal sites (n, %) | |||||||
| 0-1 | 305 (83.1) | 51 (78.5) | 355 (75.9) | 119 (79.3) | .085 | 1 | .077 |
| ≥2 | 62 (16.9) | 14 (21.5) | 113 (24.1) | 31 (20.7) | |||
| IPI risk group (n, %) | |||||||
| Low (0-1) | 140 (38.5) | 14 (21.9) | 98 (21.3) | 37 (25.5) | < .001 | .092 | < .001 |
| Low-intermediate (2) | 89 (24.5) | 17 (26.6) | 121 (26.2) | 37 (25.5) | |||
| High-intermediate (3) | 74 (20.3) | 20 (31.3) | 117 (25.4) | 42 (29) | |||
| High (4-5) | 61 (16.8) | 13 (20.3) | 125 (27.1) | 29 (20) | |||
| NA | 3 | 1 | 7 | 5 |